|
|
|
|
|
Vincristine: profile and news
Hana Biosciences Completes Licensing of Three Targeted Cancer Drug ... May 8, 2006 James Le Fanu praises plants, the most important source of the ... May 2, 2006 Teen deserves a gold medal for guts, too May 12, 2006 A Pilot Study With Long Term Follow Up of Hyperbaric Oxygen ... Apr 24, 2006 Inex Pharmaceuticals Closes Hana Biosciences Licensing Agreement May 8, 2006 Hana Biosciences Reports First Quarter 2006 Results May 4, 2006 Biogen Idec Reports First Quarter 2006 Results Apr 26, 2006 Dose-Dense Therapy for NHL Safely Administered with Support of ... Apr 18, 2006 Other information Indication For treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, acute panmyelosis Pharmacology Vincristine is a vinca alkaloid antineoplastic agent used as a treatment for various cancers including breast cancer, Hodgkin's disease, Kaposi's sarcoma, and testicular cancer. The vinca alkaloids are structurally similar compounds comprised of 2 multiringed units, vindoline and catharanthine. The vinca alkaloids have become clinically useful since the discovery of their antitumour properties in 1959. Initially, extracts of the periwinkle plant (Catharanthus roseus) were investigated because of putative hypoglycemic properties, but were noted to cause marrow suppression in rats and antileukemic effects in vitro. Vincristine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death. Vincristine has some immunosuppressant effect. The vinca alkaloids are considered to be cell cycle phase-specific. Mechanism Of Action The antitumor activity of Vincristine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Like other vinca alkaloids, Vincristine may also interfere with: 1) amino acid, cyclic AMP, and glutathione metabolism, 2) calmodulin-dependent Ca2+-transport ATPase activity, 3) cellular respiration, and 4) nucleic acid and lipid biosynthesis. Drug Category Antineoplastic Agents; ATC:L01CA02 Brand Names/Synonyms Indole alkaloid; LCR; Leurocristine; Onco TCS; Oncovin; VCR; VIN; Vincasar PFS; Vincrex; Vincristina [DCIT]; Vincristine; Vincristine Sulfate; Vincristine Sulfate PFS; Vincristinum [INN-Latin]; Vincrstine; Vincrystine; Vinkristin; 22-Oxovincaleukoblastine; EINECS 200-318-1; Oncovin (1:1 sulfate salt); Vincaleukoblastine, 22-oxo-; Vincasar (1:1 sulfate salt); Vincrex (1:1 sulfate salt); Z-D-Val-Lys(Z)-OH Dosage Forms LIQUID; SOLUTION Absorption Not Available Interactions Interactions for Vincristine: The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. Dosage adjustment should be based on serial blood level monitoring. The contribution of vincristine sulfate to this interaction is not certain. The interaction may result from reduced absorption of phenytoin and an increase in the rate of its metabolism and elimination. Chemical IUPAC Name Not Available Chemical Formula C46H56N4O10 Half Life 19-155 hours Drug Type Approved Drug # Accession No APRD00495 CAS Registry Number 57-22-7 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |